Payment overview · 2025
General Payments
$486.50
14 reported records · 9 companies
Healthcare provider profile · identity verified
Lori Jean Kueffner, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CARO, MI · NPI 1558478024
Verified facts
What the public records show
CMS Open Payments records show Lori Jean Kueffner, PA received $486.50 in general payments during 2025 across 14 reported records.
Exact Sciences Corporation accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.61 | 19.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.26 | 17.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.92 | 16.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.68 | 12.7% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.17 | 10.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.12 | 9.5% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $37.27 | 7.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.74 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.73 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.50 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $92.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.26 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $80.92 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $51.17 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 63 |
| Lisinopril | Lisinopril | 252 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 49 |
| Omeprazole | Omeprazole | 219 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 153 | 21 |
| Metformin Hcl Er | Metformin Hcl | 117 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 22 |
| Losartan Potassium | Losartan Potassium | 111 | 23 |
| Potassium Chloride | Potassium Chloride | 98 | 16 |
| Alendronate Sodium | Alendronate Sodium | 90 | 23 |
| Furosemide | Furosemide | 88 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 24 |
| Metformin Hcl | Metformin Hcl | 86 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 24 |
| Trulicity | Dulaglutide | 81 | 14 |
| Eliquis | Apixaban | 80 | 14 |
| Simvastatin | Simvastatin | 75 | 13 |
| Allopurinol | Allopurinol | 74 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 14 |
| Alprazolam | Alprazolam | 73 | 21 |
| Sertraline Hcl | Sertraline Hcl | 73 | 17 |
| Tramadol Hcl | Tramadol Hcl | 70 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 14 |
| Gabapentin | Gabapentin | 63 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 11 |
| Azithromycin | Azithromycin | 61 | 50 |
| Montelukast Sodium | Montelukast Sodium | 61 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Atenolol | Atenolol | 59 | 11 |
| Methylprednisolone | Methylprednisolone | 57 | 45 |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Fluconazole | Fluconazole | 55 | 33 |
| Bupropion Xl | Bupropion Hcl | 53 | 11 |
| Famotidine | Famotidine | 52 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | 11 |
| Trazodone Hcl | Trazodone Hcl | 50 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 15 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 27 |
| Meloxicam | Meloxicam | 43 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 25 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Acyclovir | Acyclovir | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 21 |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Glipizide | Glipizide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Prednisone | Prednisone | 16 | 12 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.50 · 14 records | Exact Sciences Corporation | AIRSUPRA, CAPLYTA, EVENITY, FANAPT, OTEZLA, PROLIA, REPATHA, REXULTI, SKYRIZI, The Cologuard Plus Collection Kit, VERQUVO, Vest Therapy Und | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error